Adjuvant radiotherapy for pathologically advanced prostate cancer improves biochemical recurrence free survival compared to salvage radiotherapy

Table 1 Patient characteristics

		Received adjuvant therapy	Adjuvant candidate and received salvage radiotherapy	P value
Age at RT (median, IQR), mo		60 (54-65)	63 (59-68)	0.2
Follow-up (mo)		53 (19-83)	50 (22-854)	0.1
Time from RP to RT, mo	0-12	43 (93%)	12 (14%)	< 0.001
	> 12-24	3 (7%)	18 (21%)
	> 24-48	0 (0%)	29 (33%)
	> 48	0 (0%)	28 (32%)
Pre-RT PSA	Undetectable	46 (100%)	0 (0%)	< 0.001
	> 0-0.2	0 (0%)	39 (46%)
	> 0.2-1.0	0 (0%)	38 (45%)
	> 1.0	0 (0%)	7 (8%)
Received	No	37 (79%)	67 (77%)	0.8
Peri-RT ADT	Yes	10 (21%)	20 (23%)
Coronary artery disease	No	36 (86%)	64 (84%)	0.8
	Yes	6 (14%)	12 (16%)
Diabetes mellitus, type II	No	37 (88%)	58 (76%)	0.1
	Yes	5 (12%)	18 (24%)
Hypertension	No	19 (45%)	37 (49%)	0.6
	Yes	23 (55%)	39 (51%)
Obesity	No	31 (74%)	51 (67%)	0.4
	Yes	11 (26%)	25 (33%)
Peripheral vascular disease	No	39 (93%)	73 (96%)	0.4
	Yes	3 (7%)	3 (4%)
Smoking history	No	37 (88%)	70 (92%)	0.5
	Yes	5 (12%)	6 (8%)
Pathologic	2-6	9 (20%)	18 (21%)	0.4
Gleason score	7	21 (48%)	48 (57%)
	8-10	14 (32%)	18 (21%)
Pathologic	T1	0 (0%)	0 (0%)	0.08
Tumor stage	T2	11 (25%)	35 (41%)
	T3/T4	33 (75%)	51 (59%)
Positive surgical margin	Absent	12 (25%)	28 (32%)	0.4
	Present	35 (75%)	59 (68%)
Extracapsular extension	Absent	20 (43%)	41 (47%)	0.6
	Present	27 (57%)	46 (53%)
Seminal vesicle invasion	Absent	37 (79%)	80 (92%)	0.03
	Present	10 (21%)	7 (8%)

RP: Radical prostatectomy; RT: Radiotherapy; IQR: Interquartile range; ADT: Androgen deprivation therapy; PSA: Prostate specific antigen.